Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2628

Raynaud’s Symptoms and Pregnancy Induced Hypertension in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2624

A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2609

A Systematic Literature Mining and Gene Expression Analysis Identifies Possible Drug Candidates for Repositioning in Lupus

9:00AM-11:00AM: Abstract Number: 2613

Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients

9:00AM-11:00AM: Abstract Number: 2584

Apremilast in Patients with Lupus Rashes

9:00AM-11:00AM: Abstract Number: 2623

Association between Smoking Status and the Clinical and Serological Characteristics at the Onset of Systemic Lupus Erythematosus. an Inception Cohort Analysis

9:00AM-11:00AM: Abstract Number: 2591

Association of Smoking and Cutaneous Manifestations in Systemic Lupus Erythematosus (SLE): Post-Hoc Results from Phase IIb Studies of Anifrolumab and Sifalimumab

9:00AM-11:00AM: Abstract Number: 2593

Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab

9:00AM-11:00AM: Abstract Number: 2627

Characterization of Emergency Department Visits in an Urban Underserved Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2582

Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2612

Disparities in Antimalarial Prescribing for Systemic Lupus Erythematosus Using a Real-World, Electronic Health Record

9:00AM-11:00AM: Abstract Number: 2588

Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV

9:00AM-11:00AM: Abstract Number: 2583

Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2599

Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2617

Electrocardiogram Abnormalities Related to Antimalarials in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2597

Explorer Study: Rituximab Use in Systemic Lupus Erythematosus, a New Look on Old Data

9:00AM-11:00AM: Abstract Number: 2586

Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE

9:00AM-11:00AM: Abstract Number: 2594

Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab

9:00AM-11:00AM: Abstract Number: 2589

Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE

9:00AM-11:00AM: Abstract Number: 2619

Hemophagocytic Syndrome in Patients from SLE Registry from the Spanish Society of Rheumatology (RELESSER)

9:00AM-11:00AM: Abstract Number: 2614

Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2596

Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients

9:00AM-11:00AM: Abstract Number: 2602

Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients

9:00AM-11:00AM: Abstract Number: 2603

Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?

9:00AM-11:00AM: Abstract Number: 2587

KZR-616, a Selective Inhibitor of the Immunoproteasome, Shows a Promising Safety and Target Inhibition Profile in a Phase I, Double-Blind, Single (SAD) and Multiple Ascending Dose (MAD) Study in Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 2616

Mesenchymal Stem Cells Induce CD1c+ Tolerogenic Dendritic Cells Via up-Regulating FLT3L in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2621

Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution

9:00AM-11:00AM: Abstract Number: 2615

Non-Pharmacological Treatment on Fatigue, Depression, Disease Activity, and Quality of Life of Systemic Lupus Erythematosus: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2601

Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart

9:00AM-11:00AM: Abstract Number: 2633

Patients with Secondary Sjögren’s Syndrome to SLE Are Characterized By Typical Autoantibodies and a Pro-Inflammatory State

9:00AM-11:00AM: Abstract Number: 2600

Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression

9:00AM-11:00AM: Abstract Number: 2606

Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study

9:00AM-11:00AM: Abstract Number: 2625

Predicting Flares in Patients with Stable Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2626

Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes

9:00AM-11:00AM: Abstract Number: 2610

Quantiferon Testing in a Clinical Trial of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2581

Safety of Hydroxychloroquine Withdrawal in Older Adults with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2585

Safety Profile in SLE Patients Treated with Atacicept in a Phase IIb Study (ADDRESS II) and Its Extension Study

9:00AM-11:00AM: Abstract Number: 2592

Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 2607

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Intravenous and Subcutaneous Single or Multiple Doses in Healthy Volounters and Subjects with Active SLE

9:00AM-11:00AM: Abstract Number: 2590

Subcutaneous Belimumab Plus Standard of Care Demonstrated Improvement in Multiple Organ Domains Versus Placebo Plus Standard of Care in Patients with Active Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 2605

Systematic Review, and Meta-Analysis of Steroid-Sparing Effect, of Biologic Agents in Randomized Placebo-Controlled Phase 3 Trials for Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2629

Systemic Lupus Erythematosus Patients Not Complaining Raynaud’s Phenomenon Display Lower Skin Blood Perfusion Than Healthy Subjects

9:00AM-11:00AM: Abstract Number: 2608

Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers

9:00AM-11:00AM: Abstract Number: 2622

The Benefit of Vitamin D on SLE Disease Activity Is Largely Explained By Renal Activity

9:00AM-11:00AM: Abstract Number: 2604

The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study

9:00AM-11:00AM: Abstract Number: 2598

The Effects of Tai Chi on Inflammatory Mediator Secretion in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2634

The Prevalence of Autoimmune Disease in Families of Patients with Systemic Lupus Erythematosus (SLE). a Single Centre Study

9:00AM-11:00AM: Abstract Number: 2595

The Role of Hydroxychloroquine in the Treatment of Undifferentiated Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 2632

The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory

9:00AM-11:00AM: Abstract Number: 2620

The Value of Repeat Biopsy in the Management of Lupus Nephritis Flares

9:00AM-11:00AM: Abstract Number: 2630

Utility of the Korean Version of Systemic Lupus Activity Questionnaire, in Clinical Practice: Its Correlation with Disease Activity Indices of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2631

Validation of Clinically Relevant Improvement in Children and Adolescents with cSLE

9:00AM-11:00AM: Abstract Number: 2611

Walk SLE – a Pilot Study Exploring Walk with Ease (WWE), a Self-Directed Walking Program, in Lupus Patients

9:00AM-11:00AM: Abstract Number: 2618

Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].